---
title: "MediPal Holdings: Net profit jumped 42.3% YoY in 1Q FY2026, prompting a major dividend forecast increase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294920884.md"
description: "Net sales rose 4.7% YoY in 1Q FY2026, with all segments contributing to growth. Operating profit declined due to higher SG&A, but net profit surged 42.3% on gains from investment securities. Full-year profit and dividend forecasts were revised upward following the PALTAC integration.Original document: MEDIPAL HOLDINGS Corporation [7459] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T06:38:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294920884.md)
  - [en](https://longbridge.com/en/news/294920884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294920884.md)
generator: "portal-rs"
---

# MediPal Holdings: Net profit jumped 42.3% YoY in 1Q FY2026, prompting a major dividend forecast increase

Net sales rose 4.7% YoY in 1Q FY2026, with all segments contributing to growth. Operating profit declined due to higher SG&A, but net profit surged 42.3% on gains from investment securities. Full-year profit and dividend forecasts were revised upward following the PALTAC integration.

Original document: MEDIPAL HOLDINGS Corporation \[7459\] Slides Release — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [7459.JP](https://longbridge.com/en/quote/7459.JP.md)
- [8283.JP](https://longbridge.com/en/quote/8283.JP.md)

## Related News & Research

- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [TLV: Strong H1 2026 profit growth and capital strength amid macroeconomic challenges](https://longbridge.com/en/news/296790736.md)
- [HCL: Strong H2 rebound, XTclave™ launch, and robust pipelines position both divisions for FY27 growth](https://longbridge.com/en/news/296840662.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**